Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
- Associated Therapies
- -
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 200
- Registration Number
- NCT06419946
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 90
- Registration Number
- NCT06336291
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT06325683
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Jasper Gerritsen
- Target Recruit Count
- 464
- Registration Number
- NCT06283927
- Locations
- 🇩🇪
Technical University Munich, Munich, Germany
🇳🇱Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 411
- Registration Number
- NCT05904119
- Locations
- 🇫🇷
CHRU de Lille, Lille, France
🇩🇪Universitaetsklinikum Koeln, Koeln, Germany
🇦🇹A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck, Austria
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- CarThera
- Target Recruit Count
- 560
- Registration Number
- NCT05902169
- Locations
- 🇫🇷
Hôpital Neurologique Pierre Wertheimer, Bron, France
🇫🇷Hôpital de La Timone, Marseille, France
🇫🇷Hôpital de la Pitié-Salpêtrière, Paris, France
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Varun Monga, MD
- Registration Number
- NCT05410301
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 225
- Registration Number
- NCT05382338
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Kaiser Permanente-Oakland, Oakland, California, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Philogen S.p.A.
- Registration Number
- NCT05304663
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 306
- Registration Number
- NCT05095376
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸Mercy Cancer Center - Carmichael, Carmichael, California, United States
🇺🇸John Muir Medical Center-Concord, Concord, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.